Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 16;10(1):17545.
doi: 10.1038/s41598-020-74000-4.

Gender differences in adverse event reports associated with antidiabetic drugs

Affiliations

Gender differences in adverse event reports associated with antidiabetic drugs

Kyung-In Joung et al. Sci Rep. .

Abstract

Little is known about gender-specific reporting of adverse events (AEs) associated with antidiabetic drugs. This study was to assess the gender-related difference in AEs reporting associated with antidiabetic agents. The number of antidiabetic drug-AE pairs associated was identified using the Korea Adverse Event Reporting System database. Prevalence of diabetes was estimated using the Health Insurance Review and Assessment Service-National Patients Sample database. Reporting rate per 10,000 people was calculated by dividing drug-AE pairs with the number of antidiabetic drug users by gender. Gender difference was presented with risk ratio (reporting rate ratio) of women to men. Antidiabetic agent-associated AEs were more frequently reported by women than men throughout body organs and drug classes. 13 out of 17 system organ class level disorders with significant gender differences were reported more often by women than men. By drug class, gender-specific reporting rates were observed in most of the drug classes, especially in newer classes such as glucagon-like peptide-1 analog (GLP1-RA), sodium glucose co-transporter-2 inhibitor (SGLT2i), and thiazolidinedione (TZD). Looking into preferred term level for each drug class, women dominated the reports of class-specific AEs of newer antidiabetic drugs such as urinary tract/genital infection (all reported by women) in SGLT2i, edema in TZD (risk ratio (RR) 12.56), and hyperglycemia in insulin users (RR 15.35). Gender differences in antidiabetic-associated AE reporting often attributed to women. Explanations for these different report levels by gender should be further investigated.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Disorders at SOCs level that demonstrated a significant difference between men and women. Rate, reporting rate per 10,000 people; Ratio, reporting rate ratio of women to men. The human body image in this figure was sourced from VectorStock, Royalty Free Vectors. https://www.vectorstock.com/royalty-free-vector/diagram-of-organs-of-the-human-body-vector-9717196 Accessed April 2019.

Similar articles

Cited by

References

    1. Cho N, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res. Clin. Pract. 2018;138:271–281. doi: 10.1016/j.diabres.2018.02.023. - DOI - PubMed
    1. Won JC, et al. Diabetes fact sheet in Korea, 2016: an appraisal of current status. Diabetes Metab. J. 2018;42:415–424. doi: 10.4093/dmj.2018.0017. - DOI - PMC - PubMed
    1. Anderson G. D. Int. Rev. Neurobiol. 2008;83:1–10. doi: 10.1016/S0074-7742(08)00001-9. - DOI - PubMed
    1. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu. Rev. Pharmacol. Toxicol. 2004;44:499–523. doi: 10.1146/annurev.pharmtox.44.101802.121453. - DOI - PubMed
    1. Tamargo J, et al. Gender differences in the effects of cardiovascular drugs. Eur Heart J Cardiovasc Pharmacother. 2017;3:163–182. doi: 10.1093/ehjcvp/pvw042. - DOI - PubMed

Publication types